Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival

Japanese Journal of Clinical Oncology

Volumn 40, Issue 3, 2009, Pages 234-240

  Lan, Chou Chin ^a,b   Wu, Yao Kuang ^a,b   Lee, Chih Hsin ^a,b   Huang, Yi Chih ^a,b   Huang, Chun Yao ^a,b   Tsai, Ying Huang ^c   Huang, Shiu Feng ^a,b   Tsao, Thomas Chang Yao ^d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer; Pleural effusion; Prognosis; Survivin

Indexed keywords

MESSENGER RNA; SURVIVIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PLEURA BIOPSY; PLEURA EFFUSION; PREDICTION AND FORECASTING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; GENETICS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950344002     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp151     Document Type: Article

References (28)

1. Marel M, Stastny B, Melínová L, Svandová E, Light RW. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 1995;107:1598-603.
2. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest 1997;111:970-80.
3. Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Böcking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-7.
4. Niwa Y, Kishimoto H, Shimokata K. Carcinomatous and tuberculous pleural effusions. Comparison of tumor markers. Chest 1985;87:351-5.
5. Targowski T, Jahnz-Rózyk K, Szkoda T, From S, Qandil N, Plusa T. Telomerase activity in transthoracic fine needle biopsy aspirates as a marker of peripheral lung cancer. Thorax 2008;63:342-4.
6. Yoshino I, Fukuyama S, Kameyama T, Shikada Y, Oda S, Maehara Y, et al. Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. Chest 2003;123:545-50.
7. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;8:917-21.
9. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
10. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, et al. Survivin gene expression in early stage non-small cell lung cancer. J Pathol 2003;200:620-6.
11. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoints by survivin. Nature 1998;396:580-4.
12. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
13. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
14. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. Expression of survivin in normal, hyperplastic and neoplastic colonic mucosa. Hum Pathol 2001;32:119-25.
15. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
16. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
17. Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007;38:986-94.
18. Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer Res 2007;109: 228-38.
19. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
20. Fallenia M, Pellegrinia C, Marchettib A, Roncalli M, Nosotti M, Palleschi A, et al. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 2005;48:211-6.
21. Wu YK, Chen KT, Kuo YB, Huang YS, Chan EC. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 2009;273:331-5.
22. Altznauer F, Martinelli S, Yousefi S, Thü rig C, Schmid I, Conway EM, et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 2004;199:1343-54.
23. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004;126:1757-63.
24. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005;128:2298-303.
25. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 2007;13:518-27.
26. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50.
27. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-8.
28. Tu SP, Jiang XH, Lin MCM, Cui JT, Yang Y, Lum CT, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003;63:7724-32.